China Resources Pharmaceutical subsidiaries report mixed Q3 2025 financials

China Resources Pharmaceutical Group announced the unaudited financial results for four of its subsidiaries for the nine months ended September 30, 2025. Dong-E-E-Jiao Company Limited reported revenue of RMB4,766,370,643.52 and a net profit of RMB1,276,768,199.27, an increase from the previous year. Similarly, Jiangzhong Pharmaceutical Co., Ltd. posted revenue of RMB2,933,172,225.19 and a net profit of RMB742,687,211.39.

In contrast, CR Double-Crane Pharmaceutical Co., Ltd. saw a slight decrease in revenue to RMB8,283,222,411.30 and net profit to RMB1,388,212,831.84 compared to the same period in 2024. KPC Pharmaceuticals, Inc. also experienced a decline in revenue, reaching RMB4,751,206,077.58, and a net profit of RMB323,404,751.99.

CR Sanjiu Medical & Pharmaceutical Company Limited reported the highest revenue among the subsidiaries, at RMB21,986,403,962.07, but its net profit decreased to RMB2,899,296,865.59 for the nine months ended September 30, 2025. These unaudited financials are prepared under PRC Generally Accepted Accounting Principles and are subject to adjustment.